Monthly Archives: February 2017

Kitsap Physical Therapy Stroke Rehabilitation Clinic New Team Member Announced

A new physical therapy team member has been announced by Kitsap Physical Therapy and Sports Clinic. Their new member of staff is Erin Jackson who is an occupational therapist and certified stroke rehab specialist.

Kitsap Physical Therapy Stroke Rehabilitation Clinic New Team Member Announced

Kingston, United States – February 28, 2017 /PressCable/

Kitsap Physical Therapy and Sports Clinic have announced that a new member has joined their team of therapists. Erin Jackson is an occupational therapist and a certified stroke rehab specialist offering her services to the Kitsap County area of Washington.

For more information, please visit: http://kitsappt.com.

Kitsap Physical Therapy and Sports Clinic is a group practice that is owned and run by its physical therapists. The website explains that they specialize in orthopedic, work and sports related injuries alongside their specialty programs and preventative care services offered by their board certified specialist. They have been offering their services since 1979 and state that they are proud to be the most recognized physical therapy provider in Kitsap County.

Their new team member, Erin Jackson, is a certified stroke rehab specialist, is registered with the National Board for certification in occupational therapy and she has a Master of Science degree in occupational therapy. She works with Jen Edwards as a team treating conditions such as strokes, traumatic brain injuries, post-concussion syndrome, multiple sclerosis, Parkinson’s disease and ALS.

She helps patients with functional tasks including feeding, dressing, grooming, toileting, bathing, sleeping, sexual function and meal prep alongside many others. Other services offered by Erin are neurological impairments, neurological vision impairments, driving evaluations, home safety evaluations, work conditioning and cognitive screening.

Mike Danford, CEO and spokesperson explains, “Occupational therapy includes an individual evaluation where the patient, caregiver and therapist come together to determine their impairments and impairments. The outcome of this is a customized plan to help improve their lives by helping them to better perform their daily living activities and reach their goals. Ongoing treatment ensures that their goals are being met and that changes are made where necessary.”

The Kitsap Physical Therapy team believes that their staff are an integral part of their identity and they work hard to find and keep the best staff available. They have 18 partners that share ownership of the business and it allows them to have at least one partner at each office.

More information is available by visiting the website on the link provided above.

Contact Info:
Name: Ceci Sittser
Organization: Kitsap Physical Therapy
Address: 26001 Barber Cut Off Road Northeast, Kingston, WA 98346, United States
Phone: +1-360-297-7050

For more information, please visit http://kitsappt.com

Source: PressCable

Release ID: 173563

Royal Road Minerals Succeeds in Bid for Caza Gold

TORONTO, ON / ACCESSWIRE / February 28, 2017 / Royal Road Minerals Limited (TSX-V: RYR) (“Royal Road Minerals” or the “Company”) announces that it has been successful in its bid to acquire Caza Gold Corp. (TSX-V: CZY) (“Caza”) under its previously announced offer (the “Offer”) made to Caza Gold’s shareholders. A total of 134,886,372 common shares of Caza, representing approximately 90% of Caza’s issued and outstanding common shares were deposited under the Offer (and not withdrawn) as at 11:59 p.m. (Pacific Time) on February 27, 2017, the expiry time of the initial deposit period under the Offer.

Royal Road Minerals has taken up all of these shares deposited under the Offer and, as a result, now holds an aggregate of 134,886,372 common shares of Caza, which represents approximately 90% of the issued and outstanding common shares of Caza, calculated on a fully-diluted basis.

Given the substantial support for the Offer, Royal Road Minerals has also extended the deposit period under the Offer for the mandatory 10-day extension period required under applicable securities laws, to enable those shareholders who have not yet tendered their shares, to deposit their Caza common shares to the Offer. The Offer, as extended, will now expire at 11:59 p.m. (Pacific Time) on March 13, 2017. All of the terms and conditions of the Offer have been complied with or waived, as applicable, and to the extent required for the take up securities deposited under Offer under applicable securities laws.

Royal Road Minerals’ President and Chief Executive Officer, Tim Coughlin said: “We are pleased that Caza’s shareholders have accepted the Offer, and we welcome them as Royal Road Minerals shareholders and as participants in our exciting growth strategy, which includes plans to advance the exploration of Caza’s key Nicaraguan properties, to continue our exploration work in the highly prospective province of Nariño in southern Colombia and to advance other initiatives elsewhere throughout Latin America.”

As further described in the Offer circular, Royal Road Minerals intends to carry out a compulsory acquisition or, alternatively, a subsequent acquisition transaction to acquire Caza common shares not deposited under the Offer. Upon completion of the compulsory acquisition or subsequent acquisition transaction, Royal Road Minerals intends to de-list the Caza shares from the TSX Venture Exchange.

Caza shareholders who tendered to the Offer will receive 0.16 of a Royal Road Minerals ordinary share for each Caza common share tendered, subject to adjustment with respect to fractional shares.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary statement:

This news release contains certain statements that constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively, “forward-looking statements”) and includes statements relating to the Offer and those describing the Company’s future plans and the expectations of its management that a stated result or condition will occur. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company and Caza, or developments in the Company’s and Caza’s business or in the mineral resources industry, or with respect to the Offer, to differ materially from the anticipated results, performance, achievements or developments expressed or implied by such forward-looking statements. Forward-looking statements include all disclosure regarding possible events, conditions or results of operations that is based on assumptions about, among other things, future economic conditions and courses of action, and assumptions related to government approvals, and anticipated costs and expenditures. The words “plans”, “prospective”, “expect”, “intend”, “intends to” and similar expressions identify forward looking statements, which may also include, without limitation, any statement relating to future events, conditions or circumstances. Forward-looking statements of the Company contained in this news release, which may prove to be incorrect, include, but are not limited to, the various assumptions set forth herein and in the Company’s take-over bid circular prepared and filed in accordance with applicable securities laws in Canada as well as the ability of the Company to obtain the requisite number of Caza shares at the expiry time of the offer, as extended, to effect a compulsory acquisition or a subsequent acquisition transaction and to de-list the Caza shares from the TSX Venture Exchange.

The Company cautions you not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. There is no guarantee that the anticipated benefits of the Offer and the Company’s and Caza’s business plans or operations will be achieved. The risks and uncertainties that may affect forward-looking statements include, among others: economic market conditions, anticipated costs and expenditures, government approvals, and other risks detailed from time to time in the Company’s and Caza’s filings with Canadian provincial securities regulators or other applicable regulatory authorities. Forward-looking statements included herein are based on the current plans, estimates, projections, beliefs and opinions of the Company management and information provided to the Company by Caza, and, except as required by law, the Company and Caza do not undertake any obligation to update forward-looking statements should assumptions related to these plans, estimates, projections, beliefs and opinions change. Nothing in this news release should be construed as either an offer to sell or a solicitation to buy or sell the Company’s securities.

For further information please contact:
Dr. Timothy Coughlin
President and Chief Executive Officer

USA-Canada toll free 1800 6389205
+44 (0)1534 887166
+44 (0)7797 742800
info@royalroadminerals.com

SOURCE: Royal Road Minerals Limited

ReleaseID: 456244

Rhyolite Resources Ltd. Announces Increase to Previously Announced Private Placement Financing

VANCOUVER, BC / ACCESSWIRE / February 28, 2017 / Rhyolite Resources Ltd. (TSX-V: RYE) (“Rhyolite” or the “Company”) reports that the previously announced brokered private placement (January 26, 2017) of up to a maximum of 16,000,000 Units at a price of $0.10 per Unit has been increased to 20,000,000 Units at a price of $0.10 per Unit for gross proceeds of $2,000,000 (the “Offering”).

Each Unit will consist of one (1) common share and one-half (1/2) share purchase warrant of Rhyolite (“Warrant”). Each whole Warrant shall entitle the holder thereof to acquire one additional common share of Rhyolite at an exercise price of $0.15 per share at any time on or before the date which is 24 months after the closing date of the Offering.

Leede Jones Gable Inc. (the “Agent”) is acting as agent for the Offering. On closing, the Company may pay the Agent a commission in cash and/or warrants.

Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals, including that of the TSX Venture Exchange.

The funds raised from the issuance of the Units shall be used to finance potential acquisitions of new properties and for general working capital purposes.

ON BEHALF OF THE BOARD OF DIRECTORS OF
RHYOLITE RESOURCES LTD.

“Richard Graham”
Director, President and CEO

For further information please contact:

Richard Graham, P.Geol.
Telephone: 604-689-1428

Cautionary Statement for Forward-Looking Information

Certain information set forth in this press release contains forward-looking statements. Specifically, this press release contains forward-looking statements concerning the anticipated use of proceeds of the Offering and the anticipated closing of the Offering. The anticipated closing date assumes that prior to that date, the Company will obtain all necessary regulatory approvals. The anticipated use of proceeds assumes that the Offering will occur as contemplated and assumes the existence of certain other conditions with respect to the capital expenditure program of the Company, general economic conditions, industry conditions, currency fluctuations, commodity prices. In each case, the risk factors that could cause actual results to vary from results expressed or implied by the forward-looking statements contained in this press release are primarily events beyond the Company’s control that preclude the Company from satisfying all applicable pre-conditions and include the risks that the Offering may not close, general economic conditions, industry conditions, currency fluctuations, volatility of commodity prices, exploration risk, escalation of operating and capital costs, the ability to access sufficient capital from internal and external sources and competition from other industry participants for, among other things, capital, services, acquisitions of new properties . These forward-looking statements may prove to be incorrect and undue reliance should not be placed on them. These forward-looking statements are made as of the date hereof and unless otherwise required by applicable law, the Company does not intend and does not assume any obligation to update or revise such forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

ReleaseID: 456243

Smart Machine System Market Share, Trend, Demand and Key Manufacturers Analysis and Forecast to 2022

ReportsWeb.com added “Global Smart Machine System Market Research Report 2017” to its vast collection of research Database. The report is spread across 102 pages and supported by 10 company leaders.

February 28, 2017 /MarketersMedia/

The Global Smart Machine System Market Research Report 2017 is a professional and in-depth study on the current state of the Smart Machine System industry. In a word, This report studies Smart Machine System in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer. Key companies included in this research are Alchemy API Inc., Apple Inc., Digital Reasoning, Google Inc., IBM Corporation, Narrative Science Inc., Microsoft Corporation, BAE Systems, Creative Virtual and Rethink Robotics.

Browse complete report @ http://www.reportsweb.com/global-smart-machine-system-market-research-report-2017

Market Segment by Region, this report splits Global into several key Region, with sales, revenue, market share and growth rate of Smart Machine System in these regions, from 2011 to 2022 (forecast), like North America, Europe, China, Japan, Southeast Asia and India. Firstly, Smart Machine System Market Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into Hardware, Software and Service. Split by application, this report focuses on consumption, market share and growth rate of Smart Machine System in each application, can be divided into Robots, Autonomous cars, Drones, Wearable device and Others.

Request for Sample @ http://www.reportsweb.com/inquiry&RW0001644616/sample

Major points from Table of Contents:

1 Smart Machine System Market Overview

2 Global Smart Machine System Market Competition by Manufacturers

3 Global Smart Machine System Production, Revenue (Value) by Region (2011-2017)

4 Global Smart Machine System Supply (Production) , Consumption, Export, Import by Regions (2011-2017)

5 Global Smart Machine System Production, Revenue (Value) , Price Trend by Type

6 Global Smart Machine System Market Analysis by Application

7 Global Smart Machine System Manufacturers Profiles/Analysis

7.1 Alchemy API Inc.
7.1.1 Company Basic Information, Manufacturing Base and Its Competitors
7.1.2 Smart Machine System Product Type, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 Alchemy API Inc. Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
7.1.4 Main Business/Business Overview
7.2 Apple Inc.
7.2.1 Company Basic Information, Manufacturing Base and Its Competitors
7.2.2 Smart Machine System Product Type, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Apple Inc. Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
7.2.4 Main Business/Business Overview
7.3 Digital Reasoning
7.3.1 Company Basic Information, Manufacturing Base and Its Competitors
7.3.2 Smart Machine System Product Type, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Digital Reasoning Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
7.3.4 Main Business/Business Overview

8 Smart Machine System Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Smart Machine System Market Forecast (2017-2022)

13 Research Findings and Conclusion

List of Tables and Figures

Figure Digital Reasoning Smart Machine System Market Share (2015 and 2016)
Table Google Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Google Inc. Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure Google Inc. Smart Machine System Market Share (2015 and 2016)
Table IBM Corporation Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table IBM Corporation Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure IBM Corporation Smart Machine System Market Share (2015 and 2016)
Table Narrative Science Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Narrative Science Inc. Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure Narrative Science Inc. Smart Machine System Market Share (2015 and 2016)
Table Microsoft Corporation Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Microsoft Corporation Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure Microsoft Corporation Smart Machine System Market Share (2015 and 2016)
Table BAE Systems Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table BAE Systems Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure BAE Systems Smart Machine System Market Share (2015 and 2016)
Table Creative Virtual Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Creative Virtual Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure Creative Virtual Smart Machine System Market Share (2015 and 2016)
Table Rethink Robotics Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Rethink Robotics Smart Machine System Production, Revenue, Price and Gross Margin (2015 and 2016)
Figure Rethink Robotics Smart Machine System Market Share (2015 and 2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Smart Machine System
Figure Manufacturing Process Analysis of Smart Machine System
Figure Smart Machine System Industrial Chain Analysis
Table Raw Materials Sources of Smart Machine System Major Manufacturers in 2015
Table Major Buyers of Smart Machine System
Table Distributors/Traders List
Figure Global Smart Machine System Production and Growth Rate Forecast (2017-2022)
Figure Global Smart Machine System Revenue and Growth Rate Forecast (2017-2022)
Figure Global Smart Machine System Price and Trend Forecast (2017-2022)
Table Global Smart Machine System Production Forecast by Regions (2017-2022)
Table Global Smart Machine System Consumption Forecast by Regions (2017-2022)

Place a Direct Purchase Order of Complete Report @ http://www.reportsweb.com/buy&RW0001644616/buy/2900

Contact Info:
Name: Sameer Joshi
Email: sales@reportsweb.com
Organization: ReportsWeb
Address: Pune, India.
Phone: +1-646-491-9876

Source URL: http://marketersmedia.com/smart-machine-system-market-share-trend-demand-and-key-manufacturers-analysis-and-forecast-to-2022/173682

For more information, please visit http://www.reportsweb.com/global-smart-machine-system-market-research-report-2017

Source: MarketersMedia

Release ID: 173682

Centurion Announces 30% Increase in Orders of Agri-Mineral Materials

VANCOUVER, BC / ACCESSWIRE / February 28, 2017 / Centurion Minerals Ltd. (TSX-V: CTN) (“Centurion”, or the “Company”) is pleased to announce that its local joint venture partner has successfully negotiated a new definitive supply contract (the “Contract”) with a highly respected agri-mineral fertilizer distributor in Argentina. The Contract commits the Argentine distributor to purchasing a minimum of 12,500 tonnes of agri-gypsum material from the Company’s Ana Sofia project in 2017, commencing in March. This represents a 30% increase in material orders for delivery in 2017.

Centurion CEO, Mr. David Tafel comments, “We are excited to add an additional Argentine agricultural distributor to our client list. This distributor has a solid history of selling agri-minerals in the country and their extensive testing and approval of our product is a testament to the quality of output at our Ana Sofia Project. Solidifying sales of an additional 12,500 tonnes of material further de-risks the project while continuing to validate the strong demand for agri-gypsum as a soil enhancement and fertilizer solution in South America.”

The Ana Sofia Project

The Company has an operating agri-gypsum pilot plant with a process design capacity of 4,000 tonnes/month. Gypsum is quarried from near-surface, flat-lying beds within the sedimentary formation that extends throughout the Ana Sofia Property. The gypsum rock is fed into a hopper leading to primary and secondary crushers, then screened and sorted into two agri-gypsum fertilizer products. The plant produces both a 2 – 4mm granular product and a powdered product (each having a minimum 85% gypsum content) that are packaged into one tonne tote bags.

The Ana Sofia Project comprises two mining concessions totaling 50 hectares (ha) in size within a larger (approximately 600 ha) exploration permit area. The Project is well situated within a region where small producers are currently extracting agricultural gypsum and selling to fertilizer distributors and farmers. An initial inferred gypsum resource for the Project was estimated (news releases – October 31; December 16, 2016), to comprise 1.47 million tonnes averaging 94.1% gypsum, using an 85% cut-off grade that is the minimum required gypsum content for commercial-quality agricultural gypsum products in Argentina.

ABOUT CENTURION

Centurion Minerals Ltd. is a Canadian-based company with an international focus on the exploration and development of agri-mineral and precious mineral projects. For additional information on the Ana Sofia project and applications of agri-gypsum, visit our website: www.centurionminerals.com

On Behalf of the Board,
“David G. Tafel”
President and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For Further Information, Contact:

David Tafel
President and CEO
604-484-2161

The Ana Sofia project has not been the subject of a feasibility study and as such there is no certainty that a potential mine will be realized or that the processing facility will be able to produce a commercially marketable product. There is a significant risk that any production from the project will not be profitable with these risks elevated by the absence of a compliant NI 43‑101 feasibility study. A mine production decision that is not based on a feasibility study demonstrating economic and technical viability does not provide adequate disclosure of the increased uncertainty and specific risks of failure associated with such a production decision. The Company has undertaken market research and studies to try to mitigate these risks. The work carried out to date is of a preliminary nature to assist in the determination as to whether the mineral product is suitable for sale and if there are markets for the mineral product. General risks inherent in the Project include the reliance on available data and assumptions and judgments used in the interpretation of such data, the speculative and uncertain nature of exploration and development costs, capital requirements and the ability to obtain financing, volatility of global and local economic climates, share price volatility, estimated price volatility, changes in equity markets, exchange rate fluctuations and other risks involved in the mineral exploration and development industry. There can be no assurance that a forward‑looking statement or information referenced herein will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward‑looking statements or information. We undertake no obligation to reissue or update any forward‑looking statements or information except as required by law.

The Ana Sofia mineral resource estimate is reported in accordance with the Canadian Securities Administrators National Instrument 43-101 and has been estimated using the CIM “Estimation of Mineral Resources and Mineral Reserves Best Practice Guidelines” dated November 23rd, 2003 and CIM “Definition Standards for Mineral Resources and Mineral Reserves” dated May 10th, 2014. Due to the relatively wide spacing of the historical quarries and the 2016 test pits, which varies between 40 m and 300 m, the Ana Sofia 2 resource described herein is categorized entirely as an inferred mineral resource. Inferred Mineral Resources are not Mineral Reserves. Mineral resources which are not mineral reserves do not have demonstrated economic viability. There has been insufficient exploration to define the inferred resources as an indicated or measured mineral resource, however, it is reasonably expected that the majority of the Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration. There is no guarantee that any part of the mineral resources will be converted into a mineral reserve in the future. The estimate of mineral resources may be materially affected by geology, environment, permitting, legal, title, taxation, socio-political, marketing or other relevant issues.

This news release contains forward looking statements concerning future operations of Centurion Minerals Ltd. (the “Company”). All forward-looking statements concerning the Company’s future plans and operations, including management’s assessment of the Company’s project expectations or beliefs may be subject to certain assumptions, risks and uncertainties beyond the Company’s control. Investors are cautioned that any such statements are not guarantees of future performance and that actual performance and exploration and financial results may differ materially from any estimates or projections. Such statements include, among others: possible variations in mineralization, grade or recovery rates; actual results of current exploration activities; actual results of reclamation activities; conclusions of future economic evaluations; changes in project parameters as plans continue to be refined; failure of equipment or processes to operate as anticipated; accidents and other risks of the mining industry; delays and other risks related to construction activities and operations; timing and receipt of regulatory approvals of operations; the ability of the Company and other relevant parties to satisfy regulatory requirements; the availability of financing for proposed transactions, programs and working capital requirements on reasonable terms; the ability of third‑party service providers to deliver services on reasonable terms and in a timely manner; market conditions and general business, economic, competitive, political and social conditions.

SOURCE: Centurion Minerals Ltd.

ReleaseID: 456239

BFK Capital Corp. and the Hydropothecary Corporation Announce TSXV Conditional Approval and Filing of Filing Statement

TORONTO, ON / ACCESSWIRE / February 28, 2017 / BFK Capital Corp. (TSX-V: BFK.P) (“BFK” or the “Company”), a Capital Pool Company, and The Hydropothecary Corporation (“THC”), are pleased to announce that BFK has received conditional approval from the TSX Venture Exchange (“TSXV”) for its previously announced Qualifying Transaction (as defined under TSXV Policy 2.4) with THC whereby BFK will acquire all of the securities of THC by way of a three-cornered amalgamation pursuant to the laws of Canada, BFK will change its name to “The Hydropothecary Corporation” and the directors and management of THC will become the directors and management of the resulting issuer (the “Transaction”). BFK and THC are also pleased to announce that BFK has filed its filing statement dated February 28, 2017 (the “Filing Statement”) with respect to the Transaction. For further details with respect to the Transaction, please see the Filing Statement which is available under BFK’s profile on SEDAR at www.sedar.com.

Assuming all conditions for closing are satisfied, it is expected that the Transaction will be completed on or around March 16, 2017. BFK received the approvals required from its shareholders to complete the Transaction on January 25, 2017, and THC has scheduled a meeting of its shareholders to seek approval for the Transaction for March 14, 2017.

“We are excited by the progress we’ve made towards our going public transaction and look forward to having more shareholders be a part of the Hydropothecary story”, says Sebastien St-Louis, CEO, Hydropothecary. “The timing couldn’t be better given Hydropothecary’s continued growth with the introduction of the H2 midmarket product line.”

On closing of the Transaction, the resulting issuer is expected to commence trading on the TSXV under the trading symbol “THCX”.

Forward-Looking Information

This press release contains forward-looking information based on current expectations. Statements about the closing of the Transaction and the parties’ ability to satisfy closing conditions and receive necessary approvals are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the Transaction will occur or that, if the Transaction does occur, it will be completed on the terms described above. BFK and THC assume no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Cautionary Statements

Completion of the transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Riccardo Forno
CEO
BFK Capital Corp.
(416) 361-2817

Sebastien St-Louis
President and CEO
The Hydropothecary Corporation
(613) 293-4515

SOURCE: BFK Capital Corp.

ReleaseID: 456237

Lawsuit for Investors in NYSE: BANC Shares Against Banc of California Inc. Announced by Shareholders Foundation

SAN DIEGO, CA / ACCESSWIRE / February 28, 2017 / The Shareholders Foundation, Inc. announces that a lawsuit was filed on behalf of certain investors in NYSE: BANC shares against Banc of California Inc. over alleged violations of Securities Laws.

Investors who purchased shares of Banc of California Inc. (NYSE: BANC) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

On October 18 2016, an article was published claiming, among other things, that certain Banc of California insiders had undisclosed ties to individuals previously accused of involvement with the collapse of Gerova Financial.

On January 23, 2017, Banc of California Inc. announced the resignation of its CEO, Steven A. Sugarman, and that the United States Securities and Exchange Commission (“SEC”) had opened an investigation into whether the Company had misled investors in its response to the October 2016 report disclosing a connection between the Banc of California and an alleged fraudster named Jason Galanis.

On January 23, 2017, a lawsuit was filed over alleged securities laws violations by Banc of California Inc. The plaintiff alleges that the Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects, including that the Company had extensive ties to an alleged “fraudster” named Jason Galanis, that, given Galanis’ history, the Company’s ties to Jason Galanis created substantial regulatory risk, that revelation of Jason Galanis’ ties to the Company could cause a substantial decline in the market price of the Company’s securities, that the Company allegedly misled investors concerning the Company’s connections with Jason Galanis, and that, as a result of the foregoing, Defendants’ positive statements about Banc of California’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

Those who purchased Banc of California Inc. (NYSE: BANC) shares should contact the Shareholders Foundation, Inc.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

CONTACT:

Shareholders Foundation, Inc.

Michael Daniels

+1 (858) 779-1554

mail@shareholdersfoundation.com

3111 Camino Del Rio North

Suite 423
San Diego, CA 92108

SOURCE: Shareholders Foundation, Inc.

ReleaseID: 456160

MRI Interventions, Inc. Announces 2016 Fourth Quarter and Full Year Results

Key 2016 Accomplishments Include Year-Over-Year Increases in Revenue of 25%, ClearPoint® Procedures of 32% and Disposable Product Revenue of 36%

IRVINE, CA / ACCESSWIRE / February 28, 2017 / MRI Interventions, Inc. (OTCQB: MRIC) today announced financial results for the fourth quarter and full year ended December 31, 2016.

2016
Highlights

“We were very pleased with fourth quarter results, as well as our accomplishments in 2016. During the last year, we established a solid foundation for the Company and a platform for continued growth. As we drive the adoption of our technology, we continue to focus on adding new sites, growing procedures, and tightly managing expenses,” said Frank Grillo, President and CEO of MRI Interventions. “Real time intra-operative MRI guidance is a significant advance in neurosurgery, and we are proud to be the leader in this field. The milestones we achieved include:

2016 Key Accomplishments:

Increased 2016 revenue by 25% over 2015, with a 36% increase in disposable products;
Grew 2016 ClearPoint procedure volume 32% over 2015, and completed more than 500 procedures for the first time in a calendar year;
Solidified our installed base of major academic medical centers and leading hospitals, ending 2016 with 47 accounts;
Increased 2016 gross margin to 59%, with further leverage available as we grow the volume of procedures;
Improved our balance sheet through reduction of debt and accumulated interest of almost $4.5 million; and
Advanced our drug delivery strategy, including sale of our SmartFlow® cannulas to six companies for use in pharmaceutical and biotech trials.

Fourth Quarter 2016 Key Accomplishments:

Increased fourth quarter 2016 disposable product revenue by 35% over the same period in 2015;
Set new Company records for quarterly revenue, disposable product revenue and ClearPoint procedures, which reached 130 in the fourth quarter of 2016; and
Tightly managed cash, resulting in a net cash burn of $1.1 million in the fourth quarter of 2016, our lowest quarterly burn rate since becoming a commercially focused company.

“2017 will be an exciting year for the Company and our technology,” Grillo continued. “Revenues are up, expenses are down, and adoption of the ClearPoint Neuro Navigation System continues to expand.”

Financial Results – Year Ended December 31, 2016

ClearPoint disposable product sales for the year ended December 31, 2016 were $4.8 million, compared with $3.5 million for the year ended December 31, 2015, representing an increase of $1.3 million, or 36%. This increase was due primarily to a greater number of procedures in 2016, which, as previously reported, exceeded 500 procedures for the first time in the Company’s history, using the ClearPoint Neuro Navigation System.

ClearPoint reusable product sales in 2016 were $831,000, compared with $907,000 in 2015. Reusable products consist primarily of computer hardware and software bearing sales prices that are appreciably higher than those for disposable products and sales volume has historically fluctuated from period to period.

Total revenues were $5.7 million in 2016, and $4.6 million in 2015, an increase of $1.2 million, or 25%.

Gross margin on product revenues in 2016 was 53%, compared to gross margin of 55% in 2015. The decrease in gross margin was due primarily to: (a) product mix differences between 2015 and 2016 in the equipment configuration of hardware and software in ClearPoint systems sold during those respective periods; (b) an increase from 2015 to 2016 in charges to the provision for obsolete and expired product; and (c) an increase in 2016, relative to 2015, in the allocation of indirect labor to production activities, commensurate with the Company’s transition from research and development to commercial activities. These factors were partially offset by increases in 2016, relative to 2015, in average unit selling prices, and decreases in 2016, relative to 2015, in average unit costs due to more favorable pricing from vendors resulting from higher order quantities.

Research and development costs were $2.6 million in 2016, compared to $2.0 million in 2015, an increase of $671,000, or 34%. The increase was due primarily to increases in: (a) costs related to the Company’s development of the next generation of the ClearPoint operating system; (b) intellectual property costs; (c) professional fees and consultants; and (d) personnel costs. Partially offsetting these factors was an increase in departmental costs allocated to production activities.

Selling, general, and administrative expenses were $8.0 million in 2016, compared with $8.4 million in 2015, a decrease of $403,000, or 5%. The decrease was primarily attributable to: (a) a decrease in personnel costs; (b) an increase in the allocation of departmental resources to production activities; (c) a decrease in medical device excise taxes, suspended by federal legislation for a two-year period beginning January 1, 2016; and (d) a decrease in non-personnel related marketing expenses. Partially offsetting these factors were increases in public company costs and professional fees. With respect to professional fees, in August 2016, the Company elected to suspend efforts then underway to sell equity units through a public offering and instead commenced a private placement of equity units that was completed in September 2016. Upon suspension of those public offering efforts, the Company capitalized certain related legal and other costs, amounting to $459,000, in anticipation of resuming public offering efforts within an estimated six-month time frame. In December 2016, the Company determined that a future public offering it might consider was not likely to be commenced within this six-month time frame, and accordingly, in the fourth quarter of 2016, the Company recorded a charge of $459,000 to general and administrative expense.

In March 2015, the Company announced the consolidation of all major business functions into its Irvine, California headquarters. In connection with this consolidation, the Company closed its Memphis, Tennessee office in May 2015, and did not retain any of its Memphis-based employees. A total of seven employees were impacted by the consolidation, including three executives. As a result, the Company incurred expense of $1.3 million primarily related to termination costs, including the modifications of option terms, in 2015.

In 2016 and 2015, the Company recorded gains of $1.1 million and $1.5 million, respectively, resulting from changes in the fair value of derivative liabilities. In 2016, such derivative liabilities related to: (a) the issuance of warrants in connection with 2012 and 2013 private placement transactions; and (b) amendments, in June and August 2016, of certain notes to add contingent conversion terms and potential down round pricing protection of warrants issued in connection with such notes. In 2015, derivative liabilities were limited to the issuance of warrants in connection with the 2012 and 2013 private placement transactions.

In April 2016, the Company entered into a securities purchase agreement with Brainlab AG (“Brainlab”) under which a note payable to Brainlab in the principal amount of $4.3 million (the “Brainlab Note”) was restructured and, among other items, the Company: (i) entered into a patent and technology license agreement with Brainlab for software relating to the Company’s SmartFrame
® device, in consideration for the cancellation of $1.0 million of the principal amount of the Brainlab Note; and (ii) issued to Brainlab, in consideration for the cancellation of approximately $1.3 million of the principal amount of the Brainlab Note, equity units, consisting of shares of the Company’s common stock and warrants to purchase shares of common stock. As a result of the foregoing, the Company recorded a debt restructuring gain of $941,000 representing the difference between (a) the aggregate fair value of the license agreement, which had no cost basis on the Company’s consolidated balance sheets, and the equity units, and (b) the aggregate principal amount of the Brainlab Note cancelled as consideration.

On June 30, 2016, the Company entered into amendments (the “Amendments”) with Brainlab, with respect to the Brainlab Note, and with two holders of secured notes payable we executed in 2014 (the “2014 Secured Notes”). Pursuant to the Amendments, the parties agreed that, in the event the Company closes a qualified public offering: (i) $2,000,000 of the principal balance of those notes, plus all unpaid accrued interest on that amount, will automatically convert into the security offered in the qualified public offering; and (ii) the exercise price for 46,207 shares of common stock underlying warrants issued in connection with those notes will be reduced as provided in the Amendments. Based on the provisions of the Amendments, on June 30, 2016, the Company recorded a non-cash loss of $820,000 resulting from the restructuring of the Brainlab Note and those 2014 Secured Notes.

On August 31, 2016, the Company entered into second amendments with the two holders of the 2014 Secured Notes that provided, in the event the Company closes a private equity offering, for: (a) the conversion to equity of an aggregate of $1.75 million of principal based on the private offering price; and (b) a reduction in the exercise price for shares of common stock that may be purchased upon exercise of warrants issued in connection with the issuance of such notes based the private offering’s terms for warrant exercise pricing. Execution of the second amendments constituted a debt extinguishment under generally accepted accounting principles, necessitating the Company to record a non-cash loss on debt restructuring of approximately $933,000, representing the aggregate difference in the fair value of the derivative liabilities between the points in time (i) immediately preceding, and (ii) immediately subsequent to, the execution of the second amendments.

Financial Results – Quarter Ended December 31, 2016

ClearPoint disposable product sales for the three months ended December 31, 2016 were $1.4 million, compared with $1.0 million for the same period in 2015, representing an increase of $354,000, or 35%. This increase was due primarily to a greater number of procedures performed using the ClearPoint Neuro Navigation System in the fourth quarter of 2016, relative to the same period in 2015.

ClearPoint reusable product sales for the three months ended December 31, 2016 were $224,000, and $438,000 for the same period in 2015.

Total revenues were $1.6 million for the three months ended December 31, 2016, and $1.5 million for the same period in 2015, an increase of $124,000, or 8%.

Gross margin on product revenues was 59% for the three months ended December 31, 2016, compared to 57% for the same period in 2015. The improvement was attributable primarily to: (a) a greater portion in the fourth quarter of 2016, compared to the same period in 2015, of revenues represented by ClearPoint disposable products, which generally have higher gross margins relative to ClearPoint reusable products; and (b) a decrease in the fourth quarter of 2016, relative to the same period in 2015, in average unit costs due to more favorable pricing from vendors resulting from higher order quantities; partially offset by (c) an increase in charges to the provision for obsolete and expired product.

Research and development costs of $530,000 for the three months ended December 31, 2016, were substantially unchanged from $523,000 for the same period in 2015. Decreases in the fourth quarter of 2016, relative to the same period in 2015, in personnel costs and third-party testing costs, were offset by increases in intellectual property costs and consulting expenses.

Selling, general and administrative expenses were $2.2 million for the three months ended December 31, 2016, compared to $1.8 million in the same period in 2015, an increase of $457,000, or 21%. This increase was due primarily to the Company’s decision, in December 2016, to write off the previously capitalized public offering costs, amounting to $459,000, discussed above.

During the three months ended December 31, 2016 and 2015, the Company recorded gains of $318,000 and $559,000, respectively, from changes in the fair value of derivative liabilities.

Reverse Stock Split

As previously announced on July 21, 2016, the Company’s Board of Directors approved a 1-for-40 reverse stock split of its issued common stock, which was effectuated on July 26, 2016. All disclosure of common shares and per share data in the accompanying condensed consolidated financial statements have been adjusted retroactively to reflect the reverse stock split for all periods presented.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company’s 2016 fourth quarter and full year financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company’s website at www.mriinterventions.com and selecting “Investors” / “News” / “IR Calendar.” The conference call may also be accessed at http://mriinterventions.equisolvewebcast.com/q4-2016. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until March 7, 2017 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company’s website at www.mriinterventions.com, on the “Investor Relations” page.

About MRI Interventions, Inc.

Building on the imaging power of magnetic resonance imaging (“MRI”), MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain. The ClearPoint Neuro Navigation System, which has received 510(k) clearance and is CE marked, utilizes a hospital’s existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.

Forward-Looking Statements

Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the Company’s ability to obtain additional financing; estimates regarding the sufficiency of the Company’s cash resources; future revenues from sales of the Company’s ClearPoint Neuro Navigation System products; and the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, both of which have been filed with the Securities and Exchange Commission, as well as the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, which will be filed with the Securities and Exchange Commission on or before March 31, 2017.

Contact:

Harold A. Hurwitz, Chief Financial Officer
(949) 900-6833

MRI INTERVENTIONS, INC.
Consolidated Statements of Operations

For The Three Months Ended December 31,

2016

2015

Revenues:

Product revenues

$
1,599,326

$
1,452,963

Other service revenues

35,779

47,088

Development service revenues

11,563

Total revenues

1,635,105

1,511,614

Cost of product revenues

676,924

646,812

Research and development costs

529,714

522,609

Selling, general, and administrative expenses

2,218,726

1,761,920

Operating loss

(1,790,259
)

(1,419,727
)

Other income (expense):

Gain on change in fair value of derivative liabilities

317,855

558,654

Other income (expense), net

6,571

(12,630
)

Interest income

1,032

1,568

Interest expense

(216,082
)

(326,300
)

Net loss

$
(1,680,883
)

$
(1,198,435
)

Net loss per share attributable to common stockholders:

Basic and diluted

$
(0.47
)

$
(0.62
)

Weighted average shares outstanding:

Basic and diluted

3,610,655

1,923,054

MRI INTERVENTIONS, INC.
Consolidated Balance Sheets

December 31,

2016

2015

ASSETS

Current Assets:

Cash and cash equivalents

$

3,315,774

$

5,408,523

Accounts receivable

865,943

1,218,043

Inventory, net

1,768,382

1,807,895

Prepaid expenses and other current assets

134,996

97,249

Total current assets

6,085,095

8,531,710

Property and equipment, net

328,249

440,606

Software license inventory

976,900

937,100

Other assets

10,641

27,306

Total assets

$

7,400,885

$

9,936,722

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current liabilities:

Accounts payable

$

1,546,926

$

697,807

Accrued compensation

666,060

557,784

Other accrued liabilities

450,424

1,398,707

Derivative liabilities

131,173

658,286

Deferred product and service revenues

223,117

116,009

Senior secured note payable, net of unamortized discount of $64,835 at December 31, 2015

4,224,609

Total current liabilities

3,017,700

7,653,202

Accrued interest

647,500

542,500

Senior note payable

2,000,000

2010 junior secured notes payable, net of unamortized discount of $2,302,472 and $2,535,230 at December 31, 2016 and 2015, respectively

697,528

464,770

2014 junior secured 12% notes payable, net of unamortized discount and deferred issuance costs aggregating $180,774 and $467,611 at December 31, 2016 and 2015, respectively

1,794,226

3,257,389

Total liabilities

8,156,954

11,917,861

Commitments and contingencies

Stockholders’ deficit:

Preferred stock, $0.01 par value; 25,000,000 shares authorized at December 31, 2016 and 2015; none issued and outstanding at December 31, 2016 and 2015

Common stock, $0.01 par value; 200,000,000 shares authorized at December 31, 2016 and 2015; 3,622,032 and 2,284,537 shares issued and outstanding at December 31, 2016 and 2015, respectively

36,220

22,845

Additional paid-in capital

93,076,475

83,722,596

Accumulated deficit

(93,868,764

)

(85,726,580

)

Total stockholders’ deficit

(756,069

)

(1,981,139

)

Total liabilities and stockholders’ deficit

$

7,400,885

$

9,936,722

MRI INTERVENTIONS, INC.
Consolidated Statements of Operations

Years Ended December 31,

2016

2015

Revenues:

Product revenues

$

5,612,857

$

4,416,036

Development service revenues

37,405

Other service revenues

136,597

140,751

Total revenues

5,749,454

4,594,192

Cost of product revenues

2,642,763

1,987,636

Research and development costs

2,628,179

1,957,332

Selling, general, and administrative expenses

7,967,250

8,370,749

Restructuring charges

1,252,584

Operating loss

(7,488,738

)

(8,974,109

)

Other income (expense):

Gain on change in fair value of derivative liabilities

1,065,935

1,539,876

Loss on debt restructuring

(811,909

)

Other income, net

216,075

230,875

Interest income

8,807

16,455

Interest expense

(1,060,065

)

(1,262,343

)

Net loss

$

(8,069,895

)

$

(8,449,246

)

Net loss per share attributable to common stockholders:

Basic and diluted

$

(2.93

)

$

(4.48

)

Weighted average shares outstanding:

Basic and diluted

2,754,803

1,884,849

MRI INTERVENTIONS, INC.
Consolidated Statements of Cash Flows

Years Ended December 31,

2016

2015

Cash flows from operating activities:

Net loss

$

(8,069,895

)

$

(8,449,246

)

Adjustments to reconcile net loss to net cash flows from operating activities:

Depreciation and amortization

155,707

211,946

Share-based compensation

959,585

1,682,063

Expenses paid through the issuance of common stock

290,245

145,987

Gain on change in fair value of derivative liabilities

(1,065,935

)

(1,539,876

)

Loss on debt restructuring

811,909

Loss on retirement of equipment

1,689

2,053

Amortization of debt issuance costs and original issue discounts

424,431

471,146

Increase (decrease) in cash resulting from changes in:

Accounts receivable

352,100

(749,094

)

Inventory

72,342

68,626

Prepaid expenses and other current assets

(37,748

)

(68,029

)

Other assets

9,811

Accounts payable and accrued expenses

178,419

(436,420

)

Deferred revenue

107,108

13,299

Net cash flows from operating activities

(5,820,043

)

(8,637,734

)

Cash flows from investing activities:

Purchases of property and equipment

(101,002

)

(76,883

)

Net cash flows from investing activities

(101,002

)

(76,883

)

Cash flows from financing activities:

Net proceeds from equity private placements

3,833,052

4,879,134

Cash paid in lieu of issuing fractional shares in reverse split of common stock

(4,756

)

Net cash flows from financing activities

3,828,296

4,879,134

Net change in cash and cash equivalents

(2,092,749

)

(3,835,483

)

Cash and cash equivalents, beginning of year

5,408,523

9,244,006

Cash and cash equivalents, end of year

$

3,315,774

$

5,408,523

SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid for:

Income taxes

$

$

Interest

$

976,295

$

223,500

SOURCE: MRI Interventions, Inc.

ReleaseID: 456156

CSX to Cut Over 1,000 Jobs

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / Warnact.com reports that on Tuesday, February 21, employees of railroad giant, CSX ,learned that the company will eliminate about 1,000 of the 2,500 management positions in its Jacksonville branch. A spokesperson for CSX, Gary Sease, referred to these layoffs as an “involuntary separation program.”

CSX did state in an email, however, that all employees who are to be laid off will receive enhanced severance pay and pension benefits, along with outplacement services. CSX, one of Jacksonville’s largest companies, employs nearly 36,000 people in the eastern U.S. in its railway, real estate, and technology operations.

This unfortunate announcement comes on the same day that CSX announced the retirement of its chief executive and chairman, Michael Ward, and President, Clarence Gooden, effective at the end of May.

According to the law firm of Levi & Korsinsky LLP, an employee advocacy firm, mass layoffs may result in employment violations. For example, the WARN Act, a federal labor law, protects employees of businesses with 100 or more employees. If an employer conducts a plant closing or mass layoff affecting 50 or more employees who constitute at least 33% of the employees at that site, or more than 500 employees at the site, the employer must provide 60 days’ advance notice. Employees are therefore entitled to full pay and benefits during such period prior to layoff and may also be entitled to various other protections under the law.

The advance notice is intended to give employees and their families transition time to adjust to the prospective loss of employment, to seek and to obtain other employment, and, if necessary, to enter skill training or retraining programs that will allow these workers to successfully compete in the job market. Oftentimes, employees don’t receive the benefits they are due, or are otherwise harmed during the layoff process and may have recourse under the law.

For more information about the WARN Act and other employee rights, contact:

Levi & Korsinsky LLP
www.WARNact.com
877-363-5972

SOURCE: Levi & Korsinsky LLP

ReleaseID: 456236

BSR Marketing’s New Amazon Marketing Agency Proudly Risks Defying Convention

{businessName} has defied convention in the digital marketing industry with the release of its new Amazon Marketing Agency. Further information can be found at https://bsrmarketing.com

San Marcos, United States – February 28, 2017 /PressCable/

Earlier today, BSR Marketing finally announced the official launch of its new Amazon Marketing Agency, which has been in development since June 2016. The main aim is to help Amazon brands of all sizes from individual sellers with a single product to large corporations with over 1,000 active listings to thrive on the world’s largest e-commerce marketplace. … but it does so, with a difference.

David Lewis, Head of Amazon Marketing and Brand Strategy at BSR Marketing, says: “We wanted to try something new with our Amazon Marketing and Sales. Anyone familiar with traditional Digital Marketing agencies will probably have noticed how they offer a wide variety of managed services, from Google PPC to Facebook Ads, without the focus and expertise unique to Amazon. This is a problem because Google SEM and traditional search ranking strategies are very different then what is required to grow and be successful on Amazon..”

So as a welcome breath of fresh air, BSR Marketing will instead specialize only in launching a product on Amazon and works to deliver clients an incredible ROI by delivering lower sponsored product costs on Amazon’s Seller Central and Amazon Marketing Services (AMS) platform. BSR Marketing chose to make this move because with all the noise surrounding various social media platforms and advertising tools, it’s easy for brands to become distracted. They believe that Amazon is in the best platform to immediately see revenue gains, while tracking, and optimizing the investment in advertising.

David Lewis also said “Amazon is constantly changing, and we want to give our customers more time to focus on other aspects of their business by having a trusted team on their side who lives and breathes Amazon. With our new Amazon marketing and advertising services, they have a fresh new possibility. We want them to feel confident that our dedicated Amazon experts are taking care of them and have them come back to us to optimize their new Amazon listings again and again. Staying focused and sometimes referring client business away to other agencies is always a risk, but it’s a risk we believe is worth taking.”

BSR Marketing has been in business since 2015, launching their new advertising service in June 2016. Since Day 1 it has always aimed to stand out from the crowd, while also providing its customers the best possible experience at the best possible value.

The new Amazon advertising service has launched and is currently available. To find out more about the service and BSR Marketing, it’s possible to visit https://bsrmarketing.com

Contact Info:
Name: David Lewis
Email: sales@bsrmarketing.com
Organization: BSR Marketing
Address: 310 S Twin Oaks Valley Rd Suite 107, San Marcos, CA 92078, United States

For more information, please visit http://bsrmarketing.com

Source: PressCable

Release ID: 173619